ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients.

Y. Qazi, F. Shihab, S. Mulgaonkar, K. MaCague, D. Patel.

University of Southern California, Los Angeles
University of Utah, Salt Lake City
Barnabas Health, West Orange
Novartis Pharmaceuticals Corporation, East Hanover.

Meeting: 2016 American Transplant Congress

Abstract number: 37

Keywords: Graft acceptance, Immunogenicity, Kidney/pancreas transplantation, Rejection

Session Information

Date: Sunday, June 12, 2016

Session Name: Concurrent Session: Kidney Transplant: CNI Minimization

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:06pm-3:18pm

Location: Room 311

Related Abstracts
  • Everolimus-Facilitated Reduction of Tacrolimus in De Novo Liver Transplant Recipients Achieves Comparable Overall Efficacy with Fewer Biopsy-Proven Acute Rejections Versus Standard Tacrolimus: 24-Month Results of a Randomized Trial
  • Only 13% of Liver Transplant (LT) Recipients with Moderate to Severe Kidney Disease (KD) Tolerate Conversion to Everolimus and Reduced Tacrolimus (EVR/rTac).

The US92 study determined whether, in de novo renal transplant patients (pts), concentration-controlled everolimus (EVR) with reduced dose tacrolimus (RTAC) is non-inferior compared to CellCept® (mycophenolate mofetil [MMF] with standard dose tacrolimus [STAC]) on measures of allograft function and safety in low and high risk pts.

In this non-inferiority (NI) study, the safety and efficacy of EVR (1.5mg/day) with RTAC was compared to MMF (2g/day) with STAC in 613 de novo renal transplant pts. The primary efficacy variable was composite efficacy failure rate (treated biopsy-proven acute rejection [tBPAR, based on local biopsy reading], graft loss, death, or loss to follow-up) at 12 months post-transplant. Three NI margins were used in the data analysis: an updated conservative NI margin (11.2%) incorporated publications through September 2014; a less conservative NI margin (12%) preserved control effect, incorporating information about standard error of historical estimatesof the control effect and information from the NI study; and an updated less conservative NI margin (15.0%) was used in the analysis.

Low-to-moderate risk pt results for the primary efficacy variables and composite endpoints (CE) are shown in the table. One additional pt in the MMF control group considered as lost to follow-up died 4 months after randomization.

Efficacy failure in low-to-moderate immunologic risk pts at 12 months

 

EVR group

n (%) N=213

MMF group

n (%) N=210

Difference in % 95% CI
Efficacy Endpoints CE1 48 (22.5) 41 (19.5) 3.0 -4.7, 10.8
tBPAR 39 (18.3) 24 (11.4) 6.9 0.1, 13.6
Graft loss 1 (0.5) 8 (3.8) -3.3 -6.1, -0.6
Death 3 (1.4) 3 (1.4) 0.0 -2.3, 2.2
Loss to follow-up 6 (2.8) 9 (4.3) -1.5 -5.0, 2.1
Graft loss or death or loss to follow-up 10 (4.7) 20 (9.5) -4.8 -9.7, 0.1
Graft loss or death 4 (1.9) 11 (5.2) -3.4 -6.9, 0.2

Based on the NI margins of 11.2%, 12.0% and 15%, NI of EVR with RTAC compared to MMF with STAC was observed in pts at low-to-moderate immunologic risk.

EVR with RTAC was efficacious for low-to-moderate risk pts. Graft rejections in the EVR group were higher yet graft loss was statistically significantly lower in this group. No unexpected safety events were found.

CITATION INFORMATION: Qazi Y, Shihab F, Mulgaonkar S, MaCague K, Patel D. Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Qazi Y, Shihab F, Mulgaonkar S, MaCague K, Patel D. Everolimus in Combination with Reduced Dose Tacrolimus Is Effective as a Prophylaxis of Acute Rejection in Low-to-Moderate Immunologic Risk De Novo Kidney Transplantation Patients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/everolimus-in-combination-with-reduced-dose-tacrolimus-is-effective-as-a-prophylaxis-of-acute-rejection-in-low-to-moderate-immunologic-risk-de-novo-kidney-transplantation-patients/. Accessed February 25, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Home
  • Search
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.